Tumor P-glycoprotein correlates with efficacy of PF-3758309 in in vitro and in vivo models of colorectal cancer

Frontiers in Pharmacology

Volumn 4 MAR, Issue , 2013, Pages

  Bradshaw Pierce, Erica Lynn ^a,b,c   Pitts, Todd M ^b,c   Tan, Aik Choon ^b,c   McPhillips, Kelly ^b   West, Mark ^a   Gustafson, Daniel L ^c,d   Halsey, Charles ^d   Nguyen, Leslie ^a   Lee, Nathan V ^a   Kan, Julie L C ^a   Murray, Brion William ^a   Eckhardt, S Gail ^b,c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Colorectal cancer; Intrinsic resistance; Mouse xenografts; P glycoprotein; Pf 3758309

Indexed keywords

ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PF 309; PF 3758309; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RNA ISOLATION; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84881501082     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00022     Document Type: Article

References (40)

1. Banck, M. S., and Grothey, A. (2009). Biomarkers of resistance to epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. Clin. Cancer Res. 15, 7492-7501.
2. Bellamy, W. T., Dalton, W. S., Kailey, J. M., Gleason, M. C., McCloskey, M., Dorr, R. T., et al. (1988). Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res. 48, 6365-6370.
3. Callegari, E., Malhotra, B., Bungay, P. J., Webster, R., Fenner, K. S., Kempshall, S., et al. (2011). A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br. J. Clin. Pharmacol. 72, 235-246.
4. Carter, J. H., Douglass, L. E., Deddens, J. A., Colligan, B. M., Bhatt, R., Pemberton, J. O., et al. (2004). Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin. Cancer Res. 10, 3448-3456.
5. Dalton, W. S., Crowley, J. J., Salmon, S. S., Grogan, M., Laufman, L. R., Weiss, G. R., et al. (1995). A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study. Cancer 75, 815-820.
6. Di, L., Whitney-Pickett, C., Umland, J. P., Zhang, H., Zhang, X., Gebhard, D. F., et al. (2011). Development of a new permeability assay using low-efflux MDCKII cells. J. Pharm. Sci. 100, 4974-4985.
7. Eswaran, J., Soundararajan, M., and Knapp, S. (2009). Targeting group II PAKs in cancer and metastasis. Cancer Metastasis Rev. 28, 209-217.
8. Fardel, O., Lecureur, V., and Guillouzo, A. (1996). The P-glycoprotein multidrug transporter. Gen. Pharmacol. 27, 1283-1291.
9. Feng, B., Mills, J. B., Davidson, R. E., Mireles, R. J., Janiszewski, J. S., Troutman, M. D., et al. (2008). In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab. Dispos. 36, 268-275.
10. Gottesman, M. M., Fojo, T., and Bates, S. E. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58.
11. Heakal, Y., Kester, M., and Savage, S. (2011). Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Ann. Pharmacother. 45, 1399-1405.
12. Jang, S. H., Wientjes, M. G., and Au, J. L. (2001a). Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Invest. New Drugs 19, 113-123.
13. Jang, S. H., Wientjes, M. G., and Au, J. L. (2001b). Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J. Pharmacol. Exp. Ther. 298, 1236-1242. Kalgutkar, A. S., Frederick, K. S., Chupka, J., Feng, B., Kempshall, S., Mireles, R. J., et al. (2009). N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7- dimethoxyquinazolin-2-amine (CP-100,356) as a "chemical knock-out equivalent" to assess the impact of efflux transporters on oral drug absorption in the rat. J. Pharm. Sci. 98, 4914-4927.
14. Kumar, R., Gururaj, A. E., and Barnes, C. J. (2006). p21-activated kinases in cancer. Nat. Rev. Cancer 6, 459-471.
15. Lee, C. A., Cook, J. A., Reyner, E. L., and Smith, D. A. (2010). P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. Expert Opin. Drug Metab. Toxicol. 6, 603-619.
16. Lee, J. S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., et al. (1994). Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol. 46, 627-638.
17. Leonard, G. D., Fojo, T., and Bates, S. E. (2003). The role of ABC transporters in clinical practice. Oncologist 8, 411-424.
18. Linn, S. C., and Giaccone, G. (1995). MDR1/P-glycoprotein expression in colorectal cancer. Eur. J. Cancer 31A, 1291-1294.
19. McGrath, T., and Center, M. S. (1988). Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res. 48, 3959-3963.
20. Molli, P. R., Li, D. Q., Murray, B. W., Rayala, S. K., and Kumar, R. (2009). PAK signaling in oncogenesis. Oncogene 28, 2545-2555.
21. Murray, B. W., Guo, C., Piraino, J., Westwick, J. K., Zhang, C., Lamerdin, J., et al. (2010). Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc. Natl. Acad. Sci. U.S.A. 107, 9446-9451.
22. Murray, S., Briasoulis, E., Linardou, H., Bafaloukos, D., and Papadimitriou, C. (2012). Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat. Rev. 38, 890-903.
23. Ong, C. C., Jubb, A. M., Haverty, P. M., Zhou, W., Tran, V., Truong, T., et al. (2011). Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc. Natl. Acad. Sci. U.S.A. 108, 7177-7182.
24. Pavlidis, P., and Noble, W. S. (2003). Matrix2png: a utility for visualizing matrix data. Bioinformatics 19, 295-296.
25. Pitts, T. M., Tan, A. C., Kulikowski, G. N., Tentler, J. J., Brown, A. M., Flanigan, S. A., et al. (2010). Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin. Cancer Res. 16, 3193-3204.
26. Pitts, T. M., Kulikowski, G. N., Tan, A. C., Murray, B. W., Arcaroli, J. J., Tentler, J. J., et al. (2013). Association of the epithelial-to-mesenchymal transition (EMT) phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Front. Pharmacol. Anti-Cancer Drugs. doi:10.3389 /fphar.2013.00035
27. Prenen, H., Tejpar, S., and van Cutsem, E. (2010). New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin. Cancer Res. 16, 2921-2926.
28. Ries, F., and Dicato, M. (1991). Treatment of advanced and refractory breast cancer with doxorubicin, vincristine and continuous infusion of verapamil. A phase I-II clinical trial. Med. Oncol. Tumor. Pharmacother. 8, 39-43.
29. Robert, J. (1999). Multidrug resistance in oncology: diagnostic and therapeutic approaches. Eur. J. Clin. Invest. 29, 536-545.
30. Sekine, I., Shimizu, C., Nishio, K., Saijo, N., and Tamura, T. (2009). A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer. Int. J. Clin. Oncol. 14, 112-119.
31. Shaw, A. T., Yeap, B. Y., Solomon, B. J., Riely, G. J., Gainor, J., Engelman, J. A., et al. (2011). Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12, 1004-1012.
32. Siddiqui, A. D., and Piperdi, B. (2010). KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann. Surg. Oncol. 17, 1168-1176.
33. Sinicrope, F. A., Hart, J., Brasitus, A., Michelassi, F., Lee, J. J., and Safa, A. R. (1994). Relationship of P-glycoprotein and carcino embryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer 74, 2908-2917.
34. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., et al. (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107-1112.
35. Sugano, K., Kansy, M., Artursson, P., Avdeef, A., Bendels, S., Di, L., et al. (2010). Coexistence of passive and carrier-mediated processes in drug transport. Nat. Rev. Drug Discov. 9, 597-614.
36. Tabusa, H., Brooks, T., and Massey, A. J. (2013). Knockdown of PAK4 or PAK1 Inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling. Mol. Cancer Res. 11, 109-121.
37. Tentler, J. J., Nallapareddy, S., Tan, A. C., Spreafico, A., Pitts, T. M., Morelli, M. P., et al. (2010). Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Mol. Cancer Ther. 9, 3351-3362.
38. Warner, E., Hedley, D., Andrulis, I., Myers, R., Trudeau, M., Warr, D., et al. (1998). Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin. Cancer Res. 4, 1451-1457.
39. Weinlander, G., Kornek, G., Raderer, M., Hejna, M., Tetzner, C., and Scheithauer, W. (1997). Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil. J. Cancer Res. Clin. Oncol. 123, 452-455.
40. Zajchowski, D. A., Karlan, B. Y., and Shawver, L. K. (2012). Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol. Cancer Ther. 11, 492-502.